SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:468a17c1-1078-4f42-8aaf-ad8face328b1"
 

Search: onr:"swepub:oai:lup.lub.lu.se:468a17c1-1078-4f42-8aaf-ad8face328b1" > Expression of HGF, ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00008350naa a2200589 4500
001oai:lup.lub.lu.se:468a17c1-1078-4f42-8aaf-ad8face328b1
003SwePub
008201028s2020 | |||||||||||000 ||eng|
009oai:DiVA.org:liu-170541
009oai:gup.ub.gu.se/296564
0247 a https://lup.lub.lu.se/record/468a17c1-1078-4f42-8aaf-ad8face328b12 URI
0247 a https://doi.org/10.1002/1878-0261.128032 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1705412 URI
0247 a https://gup.ub.gu.se/publication/2965642 URI
040 a (SwePub)lud (SwePub)liud (SwePub)gu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Sjöström, Martinu Lund University,Lunds universitet,Bröstcancer Proteogenomik,Forskargrupper vid Lunds universitet,Individuell Bröstcancerbehandling,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Bröstcancerbehandling,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breast cancer Proteogenomics,Lund University Research Groups,Personalized Breast Cancer Treatment,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Breast cancer treatment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund Univ, Sweden4 aut0 (Swepub:lu)med-msm
2451 0a Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breast-conserving surgery : a long-term follow-up of the SweBCG91-RT randomised trial
264 c 2020-09-28
264 1b Wiley,c 2020
300 a 14 s.
500 a Funding Agencies|Governmental Funding of Research within the National Health Service (ALF-agreement); Swedish Cancer SocietySwedish Cancer Society; Anna and Edwin Berger Foundation; Swedish Breast Cancer Association; Mrs Berta Kamprad Foundation; Faculty of Medicine at Lund University; Lund University Research Foundation; Skane County Research Foundation (FOU); Marcus and Marianne Wallenberg Foundation
520 a Experimental studies suggest that hepatocyte growth factor (HGF) and its transmembrane tyrosine kinase receptor, Met, in part also relying on Akt kinase activity, mediate radioresistance. We investigated the importance of these biomarkers for the risk of ipsilateral breast tumour recurrence (IBTR) after adjuvant radiotherapy (RT) in primary breast cancer. HGF, phosphorylated Met (pMet) and phosphorylated Akt (pAkt) were evaluated immunohistochemically on tissue microarrays from 1004 patients in the SweBCG91-RT trial, which randomly assigned patients to breast-conserving therapy, with or without adjuvant RT. HGF was evaluated in the stroma (HGFstr); pMet in the membrane (pMetmem); HGF, pMet and pAkt in the cytoplasm (HGFcyt, pMetcyt, pAktcyt); and pAkt in the nucleus (pAktnuc). The prognostic and treatment predictive effects were evaluated to primary endpoint IBTR as first event during the first 5 years. Patients with tumours expressing low levels of HGFcyt and pMetcyt and high levels of pAktnuc derived a larger benefit from RT [hazard ratio (HR): 0.11 (0.037–0.30), 0.066 (0.016–0.28) and 0.094 (0.028–0.31), respectively] compared to patients with high expression of HGFcyt and pMetcyt, and low pAktnuc [HR: 0.36 (0.19–0.67), 0.35 (0.20–0.64) and 0.47 (0.32–0.71), respectively; interaction analyses: P = 0.052, 0.035 and 0.013, respectively]. These differences remained in multivariable analysis when adjusting for patient age, tumour size, histological grade, St Gallen subtype and systemic treatment (interaction analysis, P-values: 0.085, 0.027, and 0.023, respectively). This study suggests that patients with immunohistochemically low HGFcyt, low pMetcyt and high pAktnuc may derive an increased benefit from RT after breast-conserving surgery concerning the risk of developing IBTR.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Akt
653 a breast cancer
653 a HGF
653 a Met
653 a radiotherapy
653 a treatment prediction
653 a Akt; breast cancer; HGF; Met; radiotherapy; treatment prediction
7001 a Veenstra, Cynthiau Linköpings universitet,Linköping University,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US4 aut0 (Swepub:liu)cynve22
7001 a Holmberg, Erik,d 1951u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology4 aut0 (Swepub:gu)xholer
7001 a Karlsson, Per,d 1963u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology4 aut0 (Swepub:gu)xkperd
7001 a Killander, Fredrikau Lund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Bröstcancerbehandling,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Breast cancer treatment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital,Lund Univ, Sweden; Skane Univ Hosp, Sweden4 aut0 (Swepub:lu)onk-fki
7001 a Malmström, Peru Lund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Bröstcancerbehandling,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Breast cancer treatment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital,Lund Univ, Sweden; Skane Univ Hosp, Sweden4 aut0 (Swepub:lu)onk-pma
7001 a Niméus, Emmau Lund University,Lunds universitet,Bröstcancerkirurgi,Forskargrupper vid Lunds universitet,Bröstcancer Proteogenomik,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Biomarkörer och Epi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breast Cancer Surgery,Lund University Research Groups,Breast cancer Proteogenomics,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Biomarkers and epidemiology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital,Lund Univ, Sweden; Skane Univ Hosp, Sweden4 aut0 (Swepub:lu)onk-ens
7001 a Fernö, Mårtenu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Individuell Bröstcancerbehandling,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Bröstcancerbehandling,Institutionen för kliniska vetenskaper, Lund,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Personalized Breast Cancer Treatment,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Breast cancer treatment,Department of Clinical Sciences, Lund,Lund Univ, Sweden4 aut0 (Swepub:lu)onk-mfe
7001 a Stål, Olleu Linköpings universitet,Linköping University,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US4 aut0 (Swepub:liu)ollst87
7102 a Bröstcancer Proteogenomikb Forskargrupper vid Lunds universitet4 org
7730 t Molecular Oncologyd : Wileyg 14:11, s. 2713-2726q 14:11<2713-2726x 1574-7891x 1878-0261
8564 u http://dx.doi.org/10.1002/1878-0261.12803x freey FULLTEXT
8564 u https://febs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1878-0261.12803
8564 u https://liu.diva-portal.org/smash/get/diva2:1476966/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://lup.lub.lu.se/record/468a17c1-1078-4f42-8aaf-ad8face328b1
8564 8u https://doi.org/10.1002/1878-0261.12803
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-170541
8564 8u https://gup.ub.gu.se/publication/296564

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view